REFERENCES

1. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol.2001;137:280-284.
2. Canadian Psoriasis Expert Panel. Integrating biological therapies into management of moderate-to-severe psoriasis: a consensus statement from a Canadian Expert Panel. Presented at: 10th International Psoriasis Symposium; June 10-13, 2004; Toronto, Canada. Poster 27.
3. Jullien D, Prinz JC, Langley RG, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action [review]. Dermatology. 2004;208:297-306.
4. RAPTIVA® (efalizumab) package insert. South San Francisco, Calif: Genentech, Inc; October 2003.
5. Gordon KB, Papp KA, Hamilton TK, et al, for the Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073-3080.
6. Gordon K, Pariser D, Langley R, et al. Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 4.
7. Leonardi CL. Efalizumab in the treatment of psoriasis. Dermatol Ther. 2004;17:393-400.
8. Lebwohl M, Tyring SK, Hamilton TK, et al, for the Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
9. Leonardi CL, Goffe B, Sobell J, et al. The safety of efalizumab in patients with moderate to severe plaque psoriasis: summary of clinical trial experience. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 613.
10. Gottlieb AB, Hamilton TK, Caro I, et al. Efficacy and safety outcomes of extended efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: an update. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster 77.
11. Carey W, Toth DP, Bissonnette R, et al. No evidence for increased risk of infection during efalizumab treatment: a review of the clinical data. Presented at: 13th Annual Congress of the European Academy of Dermatology and Venereology; November 17-21, 2004; Florence, Italy. Poster 79.
12. Toth DP, Carey W, Bissonnette R, et al. Risk of malignancy during efalizumab treatment: a review of the clinical data. Presented at: 13th Annual Congress of the European Academy of Dermatology and Venereology; November 17-21, 2004; Florence, Italy. Poster 110.
13. Papp KA, Caro I, Chastain R, et al. The safety of continuous subcutaneous efalizumab therapy for moderate to severe chronic plaque psoriasis: preliminary results from an open-label, multicenter study. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster 76.
14. Menter A, Leonardi CL, Sterry W, et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. In press.
15. Menter A, Kardatzke D, Rundle A, et al. Incidence and prevention of rebound upon efalizumab discontinuation. Presented at: 10th International Psoriasis Symposium; June 10-13, 2004; Toronto, Canada. Poster 34.
16. Carey W, Rundle AC, Kwon P, et al. Taper regimens in the management of patients discontinuing efalizumab therapy. Presented at: 10th International Psoriasis Symposium; June 10-13, 2004; Toronto, Canada. Poster 29.
17. Papp KA, Mease PJ, Garovoy MR, et al. Efalizumab in patients with psoriatic arthritis: results of a phase II, randomized, double-blind, placebo-controlled study. Presented at: 10th International Psoriasis Symposium; June 10-13, 2004; Toronto, Canada. Poster 28.
18. Enbrel® (etanercept) package insert. Thousand Oaks, Calif: Immunex Corp; April 2004.
19. Leonardi CL, Powers JL, Matheson RT, et al, for the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
20. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632.
21. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multi-study database of patients with psoriasis. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 8.
22. Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17:401-408.
23. Gottlieb AB, Goffe B, Veith J, et al. Safety of etanercept in an integrated multi-study database of patients with psoriasis. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 616.
24. Gottlieb A, Goffe B, Nakanishi A, et al. Integrated analysis of the long-term safety of etanercept in patients with psoriasis. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P91.
25. Lebwohl MG, Gottlieb AB, Whitmore JB, et al. Global safety and efficacy of more than 6 years of etanercept therapy in rheumatoid arthritis. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P87.
26. Strober B, Yamauchi P, Korman N, et al. Psoriasis patients with varying treatment histories respond similarly to etanercept therapy. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P88.
27. Papp KA, Tyring S, Wang H, et al. Impact of patient demographics on efficacy and safety of etanercept treatment in psoriasis. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P86.
28. Leonardi CL, Elewski BE, Wang H, et al. Etanercept improves all PASI subscales in patients with psoriasis. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P99.
29. Kimball AB, Woolley JM, Zitnik R. Reductions in pruritus for patients with moderate to severe psoriasis receiving etanercept therapy. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P95.
30. Elewski B, Boh E, Papp K, et al. Etanercept maintains treatment response following dose reduction in patients with psoriasis. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P93.
31. Langley RGB, Woolley JM, Stevens SR. High response due to persistent treatment of psoriasis with etanercept. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P96.
32. Krueger GC, Lebwohl MG, Wang AT, et al. Continuance on etanercept after early incomplete response in patients with psoriasis. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 546.
33. Gottlieb AB, Gordon KB, Wang AT, et al. Etanercept can safely be withdrawn from patients with psoriasis and re-establishes disease control on retreatment. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster P89.
34. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272.
35. Amevive® (alefacept) package insert. Cambridge, Mass: Biogen, Inc; May 2004.
36. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):12-16.
37. Lebwohl M, Christophers E, Langley R, et al, for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:710-727.
38. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003;2:624-628.
39. Langley R, Christophers E, Lebwohl M. Efficacy and safety of multiple courses of intramuscular alefacept in patients with chronic plaque psoriasis. Presented at: 63rd Annual Meeting of the Society for Investigative Dermatology; May 15-18, 2002; Los Angeles, Calif. Poster 820.
40. Gribetz CH, Blum R, Brady C, et al. Safety and efficacy of an extended course (16 weeks) of alefacept in the treatment of chronic plaque psoriasis. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster.
41. Menter A, Ticho B. Safety and off-treatment responses following multiple courses of alefacept in patients with chronic plaque psoriasis. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster.
42. Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis [review]. Dermatol Clin. 2004;22:407-426.
43. Gordon KB. Efficacy of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice setting. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster P590.
44. Krueger GG, van de Kerkhof P. Safety of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice setting. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster P591.
45. Menter A, Abramovits W, Cather JC. Transitioning patients with psoriasis from methotrexate to alefacept. Presented at: 10th International Psoriasis Symposium; June 10-13, 2004; Toronto, Canada. Poster 44.
46. Magliocco M, Lozano AM, Kipnis C, et al. Transitioning patients with psoriasis from cyclosporine to alefacept therapy: results of an open-label study. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY. Poster.
47. Cassetty CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 564.
48. Gottlieb AB. Expanding the use of biologic therapies in dermatology. In: Selective T-cell targeting with biologics in dermatology: increasing clinical evidence [symposium]. Presented at: 10th International Psoriasis Symposium; June 10-13, 2004; Toronto, Canada.
49. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002;46:2776-2784.
50. Schneider M, Stahl H-D, Vaishnaw AK, et al. A pilot study of the safety and efficacy of alefacept in subjects with active rheumatoid arthritis on methotrexate. Presented at: EULAR 2003; June 18-21, 2003; Lisbon, Portugal. OP0111.
51. Schneider M, Stahl H-D, Podrebarac T, et al. Tolerability and safety of combination methotrexate and alefacept in rheumatoid arthritis: results of a pilot study. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster.
52. Langley R, Baker D, Roberts J. The safety of alefacept using a reduced schedule for monitoring T cells. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 592.
53. Remicade® (infliximab) package insert. Malvern, Pa: Centocor, Inc; March 2004.
54. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
55. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-542.
56. Gottlieb AB, Evans R, Li S, et al.The efficacy of infliximab across a variety of subgroups with plaque psoriasis. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 615.
57. Gottlieb AB, Evans R, Patel K, et al. Infliximab improves signs of plaque psoriasis in patients with psoriatic arthritis. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 612.
58. Mahiques-Santos L, Martinez-Menchon T, Sanchez-Carazo JL, et al. Infliximab in the management of severe and refractory psoriasis. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster 549.
59. Papp KA. Biologics–exploring new frontiers in the treatment of psoriasis: hot off the press—a biologic update [symposium]. Presented at: 10th International Psoriasis Symposium; June 10-13, 2004; Toronto, Canada.
60. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
61. Humira® (adalimumab) package insert. North Chicago, Ill: Abbott Laboratories; January 2003.
62. Gordon KB, Leonardi C, Menter MA, et al. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. Presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Poster P2.
63. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004;17:427-431.
64. Leonardi CL. Psoriasis and psoriatic arthritis clinical trials: emerging differences among agents. In: The critical role of TNF in psoriatic disease: practical applications of using TNF antagonists [satellite symposium]. Presented at: Summer Academy 2004 of the American Academy of Dermatology; July 28-August 1, 2004; New York, NY.